Primary care management for optimized antithrombotic treatment [PICANT]: study protocol for a cluster-randomized controlled trial

Implementation Science

Volumn 7, Issue 1, 2012, Pages

  Siebenhofer, Andrea ^a   Ulrich, Lisa R ^a   Mergenthal, Karola ^a   Roehl, Ina ^a   Rauck, Sandra ^a   Berghold, Andrea ^b   Harder, Sebastian ^a   Gerlach, Ferdinand M ^a   Petersen, Juliana J ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Best practice model; Case management; Oral anticoagulation

Indexed keywords

FIBRINOLYTIC AGENT;

ARTICLE; CASE MANAGEMENT; CLINICAL PROTOCOL; HEALTH CARE PERSONNEL; HUMAN; METHODOLOGY; MULTICENTER STUDY (TOPIC); ORAL DRUG ADMINISTRATION; ORGANIZATION AND MANAGEMENT; PATIENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINE;

ADMINISTRATION, ORAL; CASE MANAGEMENT; CLINICAL PROTOCOLS; FIBRINOLYTIC AGENTS; HEALTH PERSONNEL; HUMANS; MEDICATION ADHERENCE; MULTICENTER STUDIES AS TOPIC; PATIENT EDUCATION AS TOPIC; PATIENTS; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84865328570     PISSN: None     EISSN: 17485908     Source Type: Journal    
DOI: 10.1186/1748-5908-7-79     Document Type: Article

References (42)

1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:204-233.
2. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991, 324:1865-1875.
3. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
4. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994, 74:236-241.
5. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, Lewalter T, Ravens U, Meinertz T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009, 11:423-434.
6. Dagres N, Nieuwlaat R, Vardas PE, Andresen D, Levy S, Cobbe S, Kremastinos DT, Breithardt G, Cokkinos DV, Crijns HJ. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol 2007, 49:572-577.
7. Bucheler R, Meisner C, Morike K, Fux R, Hauswald K, Lorenz G, Kuhlkamp V, Gleiter CH. Quality of antithrombotic therapy in patients with chronic atrial fibrillation: the AFib Trial. Z Arztl Fortbild Qualitatssich 2003, 97:421-431.
8. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA 1999, 281:145-150.
9. Oake N, Fergusson DA, Forster AJ, Van Walrevan C. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 2007, 176:1589-1594.
10. Saal K, Hofmann B, Blauth E, Rohe J, Beyer M, Harder S, Gerlach FM. Analyse des Behandlungsprozesses bei der oralen Antikoagulationstherapie zur Identifikation von Sicherheitsproblemen in der hausärztlichen Versorgung [Identifying safety problems in the General Practice - analysis of the treatment process of oral anticoagulation therapy]. Z Allg Med 2009, 85:148-155.
11. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
12. European Medicines Agencies (EMA): European Medicines Agencies updates on safety of Pradaxa www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/11/WC500117818.pdf..
13. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
14. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010, 103:572-585.
15. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006, 367:404-411.
16. Christensen TD, Johnsen SP, Hjortdal VE, Hasenkam JM. Self-management of oral anticoagulant therapy: a systematic review and meta-analysis. Int J Cardiol 2007, 118:54-61.
17. Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R, Bradford K, Tyndel S, onso-Coello P, Ansell J, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012, 379:322-334.
18. Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U. Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial. Thromb Haemost 2008, 100:1089-1098.
19. Siebenhofer A, Hemkens LG, Rakovac I, Spat U, Didjurgeit U. Self-management of oral anticoagulation in elderly patients - effects on treatment-related quality of life. Thromb Res 2012, 130(3):e60-e66. Epub 2012 Jul 1..
20. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. Milbank Q 1996, 74:511-544.
21. Norris SL, Nichols PJ, Caspersen CJ, Glasgow RE, Engelgau MM, Jack L, Isham G, Snyder SR, Carande-Kulis VG, Garfield S, et al. The effectiveness of disease and case management for people with diabetes. A systematic review. Am J Prev Med 2002, 22:15-38.
22. Gensichen J, von Korff M, Peitz M, Muth C, Beyer M, Guthlin C, Torge M, Petersen JJ, Rosemann T, Konig J, et al. Case management for depression by health care assistants in small primary care practices: a cluster randomized trial. Ann Intern Med 2009, 151:369-378.
23. von Korff M, Goldberg D. Improving outcomes in depression. BMJ 2001, 323:948-949.
24. Rosemann T, Joos S, Laux G, Gensichen J, Szecsenyi J. Case management of arthritis patients in primary care: a cluster-randomized controlled trial. Arthritis Rheum 2007, 57:1390-1397.
25. Gensichen J, Muth C, Butzlaff M, Rosemann T, Raspe H, de Cornejo GM, Beyer M, Harter M, Muller UA, Angermann CE, et al. Die Zukunft ist chronisch: das Chronic Care-Modell in der deutschen Primärversorgung. Übergreifende Behandlungsprinzipien einer proaktiven Versorgung für chronische Kranke [The future is chronic: German primary care and the Chronic Care Model. The comprehensive principles in the proactive treatment of the chronically ill]. Z Arztl Fortbild Qualitatssich 2006, 100:365-374.
26. Guethlin C, Beyer M, Erler A, Gensichen J, Hofmann B, Mergenthal K, Müller V, Muth C, Petersen JJ, Gerlach FM. Rekrutierung von Hausarztpraxen für Forschungsprojekte. Erfahrungen aus fünf allgemeinmedizinischen Studien [Recruitment of family practitioners for research. Experiences from five studies]. Z Allg Med 2012, 88:173-181.
27. Schafer I, Hansen H, Schon G, Maier W, Hofels S, Altiner A, Fuchs A, Gerlach FM, Petersen JJ, Gensichen J, et al. The German MultiCare-study: Patterns of multimorbidity in primary health care - protocol of a prospective cohort study. BMC Health Serv Res 2009, 9:145. 145..
28. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005, 3:692-694.
29. Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U. Self-management of oral anticoagulation in the elderly: rationale, design, baselines and oral anticoagulation control after one year of follow-up. A randomized controlled trial. Thromb Haemost 2007, 97:408-416.
30. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993, 69:236-239.
31. The EuroQol Group EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. The EuroQol Group.
32. Goetz K, Freund T, Gensichen J, Miksch A, Szecsenyi J, Steinhaeuser J. Adaptation and psychometric properties of the PACIC short form. Am J Manag Care 2012, 18:55-60.
33. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24:67-74.
34. Hua TD, Vormfelde SV, Abu AM, Schneider-Rudt H, Sobotta P, Friede T, Chenot JF. Practice nursed-based, individual and video-assisted patient education in oral anticoagulation - protocol of a cluster-randomized controlled trial. BMC Fam Pract 2011, 12:17.
35. Man-Son-Hing M, Laupacis A, O'Connor AM, Biggs J, Drake E, Yetisir E, Hart RG. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA 1999, 282:737-743.
36. Letiliniengruppe Hessen: Hausärztliche Leitlinie Antikoagulation [Guideline Anticoagulation for General Practitioners] [www.leitlinien.de/leitlinienanbieter/deutsch/pdf/hessenantikoagulation]..
37. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin [German Society of General Practice and Family Medicine]: Gerinnungshemmung [Oral anticoagulation] [http://leitlinien.degam.de/uploads/media/Gerinnungshemmung.pdf]..
38. Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, Song F. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007, 11:iii-66.
39. Campbell MJ, Donner A, Klar N. Developments in cluster randomized trials and statistics in medicine. Stat Med 2007, 26:2-19.
40. Campbell MJ. Cluster randomized trials in general (family) practice research. Stat Methods Med Res 2000, 9:81-94.
41. World medical association declaration of Helsinki [http://www.wma.net/en/30publications/10policies/b3/]..
42. ISMP's List of High-Alert Medications [www.ismp.org/Tools/highalertmedications.pdf]..